Harnessing the Immune System in the Treatment of Cancer: New Agents in the Clinic

Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre. Dr. Siu currently serves on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. In 2016, she is awarded the University of Toronto Department of Medicine Eaton Scholar Researcher. She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10, and the Chairperson of the AACR Education Committee and Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting. Dr. Siu has published over 240 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for the Journal of Clinical Oncology and JAMA Oncology.